Abiopharma

🔍 SING GEORGE L (Director)

Company: REGENERON PHARMACEUTICALS, INC. (REGN)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 155 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 31,007.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: H | nature_of_ownership: by Spouse | shares_owned_after: 750.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: H | nature_of_ownership: by Spouse/Cust Son | shares_owned_after: 400.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: H | nature_of_ownership: by Trust for Son | shares_owned_after: 1,000.00
• Acquired 1,962 shares of Non-Qualified Stock Option (right to buy) at $772.76 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-02 | equity_swap_involved: 0 | shares_owned_after: 1,962.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
• F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.